Despite these limitations, our analysis offers practical insights, particularly given the paucity of studies on the timing of cerebral infarction onset associated with anti-VEGF therapy and may contribute to a better understanding of drug safety in clinical practice. This evidence concerns the gene VEGFA and cerebral infarction.